SGLT2 inhibitors are a class of medications used primarily for the treatment of type 2 diabetes. These drugs work by blocking the sodium-glucose co-transporter 2 protein in the kidneys, which helps to lower blood sugar levels by increasing the excretion of glucose in the urine. In addition to their glucose-lowering effects, SGLT2 inhibitors have also been shown to have potential benefits for cardiovascular health and weight loss. Some common SGLT2 inhibitors include empagliflozin, canagliflozin, and dapagliflozin.